Chinese Hamster Ovary (i.e., Cho) Patents (Class 435/358)
-
Publication number: 20140107034Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: ZymoGenetics, Inc.Inventors: Carl W. BIRKS, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
-
Publication number: 20140106401Abstract: Described is a DNA molecule comprising an open reading frame sequence encoding a selectable marker polypeptide, wherein the DNA molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a GTG or TTG start codon, and wherein the ORF sequence that encodes the selectable marker protein has been mutated to replace at least half of its CpG dinucleotides as compared to the native ORF sequence that encodes the selectable marker protein. Further provided are such DNA molecules wherein the ORF sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest. Also described are methods for obtaining host cells expressing a polypeptide of interest, wherein the host cells comprise the DNA molecules described herein.Type: ApplicationFiled: November 15, 2013Publication date: April 17, 2014Applicant: ChromaGenics B.V.Inventors: Arie Pieter Otte, Henricus J.M. van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt
-
Publication number: 20140105855Abstract: IL-17 Receptor binding proteins, including non-naturally occurring and recombinantly modified proteins, methods of making and using such molecules as therapeutic, prophylactic and diagnostic agents are provided.Type: ApplicationFiled: April 6, 2012Publication date: April 17, 2014Inventor: Kenan Christopher Garcia
-
Patent number: 8697440Abstract: The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and ?-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated protein.Type: GrantFiled: November 19, 2010Date of Patent: April 15, 2014Assignee: Medimmune LimitedInventors: Christel Fenge, Ann Lövgren, Anders Thelin
-
Publication number: 20140100338Abstract: The invention relates to a method for the enzyme-catalysed hydrolysis of polyacrylic acid esters. According to said method, at least one polyacrylic acid ester is provided and incubated with at least one enzyme selected from enzymes (EC 3.1) acting on ester bindings, until the ester groups contained in the polyacrylic acid ester are partially or fully hydrolytically split, and optionally the modified polymer obtained thereby is isolated. The invention also relates to the enzymes used and mutants thereof, nucleic acids coding for the enzymes, vectors comprising the nucleic acids, micro-organisms comprising the vectors, and the use of the enzymes, the vectors or the micro-organisms for carrying out a method for the enzyme-catalysed hydrolysis of polyacrylic acid esters. The present application also relates to polymer reaction products that can be obtained by the method, and methods for producing esterases.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: BASF SEInventors: Bernhard Hauer, Hans Wolfgang Höffken, Cecilia Kvarnström Branneby, Helmut Schwab, Sabine Feichtenhofer, Marlene Buchebner, Brigitte Pohn
-
Publication number: 20140099711Abstract: Methods and perfusion culture systems are disclosed. The systems and methods relate to decreasing the starting perfusion rate, resulting in increased residence time of the cells in the bioreactor and the cell retention device, and/or concomitantly increasing the starting bioreactor volume or decreasing the starting cell retention device volume, or both. Other method embodiments include increasing the concentrations of individual components of the tissue culture fluid, and adding a stabilizer of the degradation of the recombinant protein.Type: ApplicationFiled: October 9, 2013Publication date: April 10, 2014Inventors: Yuval Shimoni, Volker Moehrle, Venkatesh Srinivasan
-
Publication number: 20140101785Abstract: Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of G-protein coupled receptor (GPCR) or ion channels and methods of monitoring neural activity also are provided.Type: ApplicationFiled: March 13, 2013Publication date: April 10, 2014Applicant: HOWARD HUGHES MEDICAL INSTITUTEInventors: Loren Looger, Karel Svoboda, Douglas Kim, Rex Kerr
-
Patent number: 8691531Abstract: The present invention is directed to compositions of matter comprising nucleic acids encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 207 or 208, encoding an anti-CD79b antibody comprising the heavy chain variable domain sequence of SEQ ID NO: 207 and the light chain variable domain sequence of SEQ ID NO: 208, or encoding an anti-CD79b antibody having : (i) a variable light chain comprising a HVR-L1 having the sequence of SEQ ID NO: 194, a HVR-L2 having the sequence of SEQ ID NO: 195, and a HVR-L3 having the sequence of SEQ ID NO: 196 and (ii) a variable light chain comprising a HVR-H1 having the sequence of SEQ ID NO: 202, a HVR-H2 having the sequence of SEQ ID NO: 203, and a HVR-H3 having the sequence of SEQ ID NO: 204, and vectors and host cells thereof.Type: GrantFiled: November 28, 2011Date of Patent: April 8, 2014Assignee: Genentech, Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Publication number: 20140094404Abstract: The invention relates to conjugates comprising a targeting moiety specific for the CXCR4 based on the polyphemusin-derived peptide and a therapeutic or imaging agent. The invention relates as well to the application of said conjugates for the therapy and diagnostics which require the specific targeting to CXCR4+ cells.Type: ApplicationFiled: January 13, 2012Publication date: April 3, 2014Inventors: Antonio Pedro Villaverde Corrales, Esther Vázquez Gómez, Neus Ferrer Miralles, Ugutz Unzueta Elorza, Ramón Mangues Bafalluy, Maria Virtudes Céspedes Navarro, Isolda Casanova Rigat
-
Publication number: 20140096274Abstract: The present invention relates to variants of TNF family ligands which have been mutated at the ligand trimerisation interface so that they are not capable of assembling into trimers, and either assemble into dimers or remain as monomers. Such ligands bind to the TNF receptor but are unable to activate it, effectively functioning as competitive inhibitors. The invention also relates to nucleic acids encoding the variants of TNF family ligands, vectors and host cells comprising the nucleic acid and methods for the treatment of diseases associated with aberrant signalling through a TNF receptor.Type: ApplicationFiled: December 23, 2011Publication date: April 3, 2014Inventors: Wilhelmus Johannes Quax, Vicente R. Tur, Luis Serrano, Albert Martinus Van Der Sloot, Robbert H. Cool, Aart H.G. Van Assen
-
Publication number: 20140087426Abstract: This application provides transcription activator-like effector nucleases (TALENs), polynucleotide sequences encoding the TALENs, expression cassettes for producing TALENs to target cleavage of nucleic acids, and methods of producing and using the TALENs.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicant: The Chinese University of Hong KongInventors: Yun LIU, Christopher H.K. Cheng
-
Publication number: 20140079643Abstract: The present invention relates to a novel protein skeletal module which increases the binding affinity or binding specificity of active polypeptides. More particularly, the present invention relates to a protein skeletal module comprising polypeptides consisting of the 1st to 19th amino acids of the amino acid sequence expressed in sequence number 1; polypeptides comprising active polypeptides; and polypeptides consisting of the 29th to 86th amino acids of the amino acid sequence expressed in sequence number 1. The present invention also relates to a method for preparing the protein skeletal module. The protein skeletal module of the present invention increases the binding affinity or binding specificity of active polypeptides embedded therein, and therefore is effective in diagnosing and treating diseases.Type: ApplicationFiled: October 18, 2013Publication date: March 20, 2014Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Kiweon CHA, In-Seop So, Soyoun Kim, Byung-Heon Lee, In San Kim
-
Publication number: 20140073019Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.Type: ApplicationFiled: March 7, 2012Publication date: March 13, 2014Applicant: PURAC BIOCHEM B.V.Inventors: Nick Johannes Petrus Werckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
-
Publication number: 20140072561Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.Type: ApplicationFiled: September 17, 2013Publication date: March 13, 2014Applicant: CSL BEHRING GMBHInventors: Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
-
Publication number: 20140073577Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7 and/or Nav1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 16, 2012Publication date: March 13, 2014Applicant: AMGEN INC.Inventors: Justin K. Murray, Leslie P. Miranda, Stefan I. McDonough
-
Publication number: 20140073007Abstract: The present invention provides a polynucleotide and a method for screening and enriching a recombinant protein expressed in a eukaryotic cell, the polynucleotide comprising a tricistronic expression cassette comprising a) a promoter, b) a gene of interest (GOI), c) a reporter gene, d) a selection marker gene, e) an internal ribosome entry site (IRES) element, and f) a 2A element. Said method comprises a) transfecting or transducing suitable eukaryotic host cells with the polynucleotides of the present invention, b) culturing the eukaryotic host cells under conditions so as to express the protein of interest, the reporter protein and the selection marker protein in a cell culture selection medium suitable for selecting positively-transfected/transduced cells by means of said selection marker, and c) screening, sorting and/or enriching the cells expressing high levels of protein of interest by means of the reporter protein.Type: ApplicationFiled: August 20, 2013Publication date: March 13, 2014Applicant: Miltenyi Biotec GmbHInventors: Anne SCHÜLER, Nicole Susann ECKARDT, Iris BÜRGER
-
Patent number: 8669109Abstract: A new method for selecting clones and recloning mammalian cells which are of importance for the production of biopharmaceuticals, preferably hamster or mouse myeloma cells, with a high degree of automation and throughput. The invention relates to methods of depositing and replicating single cell clones of the cells in question. The invention also relates to methods of preparing proteins using cells which have been obtained and replicated by single cell deposition as well as compositions which allow the replication of single cells.Type: GrantFiled: October 7, 2010Date of Patent: March 11, 2014Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Ralf Otto, Barbara Enenkel, Juergen Fieder, Thomas Krieg
-
Publication number: 20140066378Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.Type: ApplicationFiled: July 13, 2013Publication date: March 6, 2014Inventors: Surjit Bhimarao DIXIT, Igor Edmondo Paolo D'ANGELO, Mario SANCHES, Gordon Yiu Kon NG
-
Publication number: 20140065172Abstract: The present invention relates to a delivery system that comprises a conjugate that facilitates the delivery of a compound such as a biologically-active macromolecule, a nucleic acid or a peptide in particular, into a cell. The present invention also relates to said conjugate for delivery of a compound, such as a biologically-active macromolecule, a nucleic acid or a peptide, into a cell. The present invention further relates to a pharmaceutical composition comprising said conjugate and to its use. The present invention also relates to a method of delivering a compound to a cell or an organism, preferably a patient.Type: ApplicationFiled: January 26, 2012Publication date: March 6, 2014Inventors: Christophe J. Echeverri, Birte Sönnichsen, Reinhard Wähler, Mike Werner Helms, Brian S. Sproat
-
Patent number: 8663945Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: November 30, 2011Date of Patent: March 4, 2014Assignee: AbbVie IncInventors: Itzcoatl A. Pla, Joseph C. Matuck, John C. Fann, Christof Schulz, Nicole A. Roy, David F. Bruton, James McIntire, David Chang Yu-Hsiang, Thomas Seewoester
-
Patent number: 8663985Abstract: An anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell is described. The anchoring/capturing system comprises a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and a second antibody or a second antigen-binding fragment for binding the secreted product. Uses and methods involving the anchoring/capturing system are provided.Type: GrantFiled: May 2, 2011Date of Patent: March 4, 2014Assignee: Miltenyi Biotec GmbHInventors: Stefan Miltenyi, Susanne Hoher-Peters, Monika Winkels
-
Patent number: 8663989Abstract: The present invention relates to methods of host cell transduction utilizing ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of Friend murine leukaemia virus, in particular the envelope encoded by molecular clone PVC-211 and the host cell may be engineered to recombinantly express the Reel receptor. The retroviral vector particles and methods of the invention can be used to introduce expressible polynucleotide sequences of interest into host cells with high efficiency. This results in protein production methods with higher yield (mg/L) and a reduction in manufacturing costs that could be used in a range of applications including for example, the production of therapeutic proteins, vaccines and antibodies.Type: GrantFiled: November 22, 2010Date of Patent: March 4, 2014Assignee: 4-Antibody AGInventor: Jörn Stitz
-
Publication number: 20140057335Abstract: The present invention is directed generally to cell culture media useful for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells in the presence of said media. Cells containing introduced materials can be further cultured in the media. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly eukaryotic cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention thus provides efficient and high throughput methods to transform/transfect culture and cells avoiding the need for multiple manipulations and transfers of cells during transfection and expression studies.Type: ApplicationFiled: August 15, 2013Publication date: February 27, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Valentina C. CICCARONE, Dale Gruber, Shelly Bennett
-
Publication number: 20140058790Abstract: Methods and compositions described herein relate to processes for the production of deuterated peptides, and the deuterated peptides produced accordingly. Deuterated peptides produced according to methods and compositions described herein may be produced more efficiently than such peptides produced according to prior art processes. The production process of according to methods and compositions described herein may lead to advantages in yield, purity, and/or price for deuterated peptides. Methods of marketing deuterated peptides are also disclosed.Type: ApplicationFiled: November 30, 2011Publication date: February 27, 2014Applicant: AmideBio LLCInventors: Michael H.B. Stowell, Mikhail Plam
-
Publication number: 20140051124Abstract: The present disclosure relates to methods of decreasing lactate production in cell culture using divalent transitional metallic salts. The present disclosure also relates to a method of producing polypeptide by adding divalent transitional metallic salt to the cell culture medium for reducing lactate accumulation followed by fermenting and recovering the polypeptide.Type: ApplicationFiled: April 27, 2012Publication date: February 20, 2014Inventors: Ruchika Srivastava, Sneha Lakshmandas Hemdev, Ankur Bhatnagar, Saravanan Desan, Anuj Goel, Harish Iyer, Vana Raja, Lavanya Rao
-
Publication number: 20140051630Abstract: A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed. Isolation of a nucleic acid encoding a periostin isoform, panc, is also taught.Type: ApplicationFiled: January 28, 2013Publication date: February 20, 2014Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: Michael RUDNICKI, Johnathan SMID
-
Publication number: 20140050693Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: ApplicationFiled: August 9, 2013Publication date: February 20, 2014Applicant: TECHNISCHE UNIVERSITAT MUNCHENInventors: Ame Skerra, Ina Theobald, Martin Schlapschy
-
Publication number: 20140044773Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: May 7, 2013Publication date: February 13, 2014Inventor: Portola Pharmaceuticals, Inc.
-
Publication number: 20140044699Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: September 13, 2013Publication date: February 13, 2014Applicants: ALTIF LABORATORIES INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Hitoshi SAKURABA, Youichi TAJIMA, Ikuo KAWASHIMA, Seiichi AIKAWA, Fumiko AIKAWA
-
Patent number: 8647842Abstract: The present invention provides methods for producing a fusion protein capable of binding vascular endothelial cell growth factor (VEGF). The methods of the invention comprise growing recombinant cells in suspension culture, wherein the recombinant cells contain an expression vector comprising a nucleic acid molecule encoding a fusion protein that binds VEGF, and isolating the fusion protein from the suspension culture. The fusion protein may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.Type: GrantFiled: April 5, 2012Date of Patent: February 11, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
-
Patent number: 8647870Abstract: A biological photoreceptor, which is a directly light-controlled ion channel, including (i) an apoprotein and (ii) a light-sensitive polyene covalently bound to the apoprotein, the polyene interacting with the apoprotein and functioning as a direct light-sensitive gate.Type: GrantFiled: April 23, 2012Date of Patent: February 11, 2014Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Publication number: 20140038180Abstract: The invention provides a comprehensive, rapid, unbiased, and accurate method for identifying and/or discovering disease-associated genetic variations, e.g., disease-associated variations. The present invention further provides novel disease-associated genetic variations for use as genetic markers of disease, e.g., cancer. The invention further provides methods for assessing an individual's risk for developing a disease, e.g., cancer, by detecting the presence the novel disease-associated genetic variations of the invention.Type: ApplicationFiled: May 24, 2013Publication date: February 6, 2014Applicant: BRIGHAM & WOMEN'S HOSPITALInventors: David John Sugarbaker, Raphael Bueno
-
Publication number: 20140037717Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: September 5, 2013Publication date: February 6, 2014Applicant: Kineta Two, LLCInventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
-
Publication number: 20140038234Abstract: A short human genomic nucleotide sequence from the SAR3 region of the human interferon ?2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.Type: ApplicationFiled: March 20, 2012Publication date: February 6, 2014Applicant: National Research Council of CanadaInventor: Yves Durocher
-
Publication number: 20140038908Abstract: The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are disclosed for evaluating conditions such as preeclampsia utilizing matador polypeptides and polynucleotides encoding same.Type: ApplicationFiled: February 28, 2013Publication date: February 6, 2014Applicant: MT. SINAI HOSPITALInventors: Isabella Caniggia, Martin Post, Nima Soleymanlou, Andrea Jurisicova
-
Publication number: 20140038233Abstract: There is provided an expression vector for animal cell having an increased gene expression efficiency, and particularly, an expression vector for animal cells including a MAR element and a SAR element, which are gene expression increasing factors, at a 5? end of a promoter, a 3? end of a transcription termination site, or at both of the 5? end of the promoter and the 3? end of the transcription termination site. The expression vector for animal cells according to the present invention exhibits remarkably increased gene expression efficiency as compared to conventional expression vectors for animal cells, such that protein expression of foreign genes may be significantly increased using this expression vector for animal cells. Particularly, the expression vector for animal cells according to the present invention may be useful in that a high-expression cell line may be secured even without MTX amplification.Type: ApplicationFiled: March 30, 2012Publication date: February 6, 2014Applicant: PANGEN BIOTECH INC.Inventors: Jaeseung Yoon, Kwanghee Baek, Taeho Byun, JeongSoo Park
-
Publication number: 20140030247Abstract: Modified therapeutic proteins are provided. In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided.Type: ApplicationFiled: March 15, 2013Publication date: January 30, 2014Inventors: Edwin L. Madison, Christopher Thanos
-
Patent number: 8637315Abstract: Processes vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially Chinese Hamster Ovary (CHO) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional oriP sequences in all plasmids, the use of codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs the use of a fusion protein between a truncated Epstein-Barr virus nuclear antigenen-1c (EBNA1c) protein and a herpes simplex virus protein VP16, the use of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (FGF) and/or the use of protein kinase B to potentiate heterologous gene expression enhancement by valproic acid (VPA).Type: GrantFiled: March 9, 2009Date of Patent: January 28, 2014Assignee: National Research Council of CanadaInventors: Yves Durocher, Martin Loignon
-
Publication number: 20140024076Abstract: The technology relates in part to production (i.e., expression) of recombinant viral fusion glycoproteins and nucleic acids that encode such viral fusion glycoproteins. In some embodiments, human respiratory syncytial virus fusion protein (RSV-F) and human parainfluenza virus 3 fusion protein (hPIV3-F) are expressed.Type: ApplicationFiled: January 27, 2012Publication date: January 23, 2014Applicant: MEDIMMUNE, LLC.Inventors: Roderick Tang, Gregory M. Hayes, Heather Lawlor, Peifeng Chen, Yi Liu
-
Publication number: 20140024015Abstract: The invention provides an isolated Boone cardiovirus, Boone cardiovirus polypeptides, polynucleotides and antibodies specific for Boone cardiovirus polypeptides. Also provided are methods for detection of Boone cardiovirus.Type: ApplicationFiled: March 7, 2013Publication date: January 23, 2014Inventors: Lela Kay Riley, Judith D. Gohndrone, Matthew Howard Myles
-
Publication number: 20140017679Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.Type: ApplicationFiled: April 17, 2013Publication date: January 16, 2014Applicant: BioNTech AGInventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
-
Publication number: 20140010799Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.Type: ApplicationFiled: February 14, 2013Publication date: January 9, 2014Applicant: Millenium Pharmaceuticals, Inc.Inventor: Millenium Pharmaceuticals, Inc.
-
Publication number: 20140011237Abstract: The present invention is related to a Chinese hamster ovary cell line as deposited with the European Collection of Cell Cultures (ECACC) under accession number 10090201; use of the cell line for the production of a recombinant polypeptide; a kit comprising the cell line; and methods for the production of recombinant polypeptide.Type: ApplicationFiled: September 14, 2011Publication date: January 9, 2014Applicant: MedImmune LimitedInventors: Diane Hatton, Ray Field, Wyn Forrest-Owen, Victoria Richardson
-
Patent number: 8623644Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.Type: GrantFiled: May 28, 2010Date of Patent: January 7, 2014Assignee: Roche GlycArt AGInventors: Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey
-
Publication number: 20140005368Abstract: A method of selecting cells having zero fucose level useful as host cells for expressing recombinant proteins is disclosed. The method comprises: (d) introducing genetic mutations into a population of CHO cells by contacting the cells with a methotrexate (MTX), (e) contacting the population of CHO cells comprising mutated cells with a non-toxic fucose binding agent for an amount of time that allows binding of the fucose binding agent to a fucose moiety on a cell membrane of the population of cells, wherein the amount of time does not allow killing of the cells; and (f) depleting from the population of cells comprising mutated cells, a subpopulation of cells which bind the fucose binding agent, thereby selecting cells useful as host cells for expressing recombinant proteins, the selected cells having zero fucose content. There are also disclosed cells and cell lines useful as host cells for expressing recombinant proteins.Type: ApplicationFiled: March 5, 2012Publication date: January 2, 2014Applicant: Merck Serono S.A.Inventors: Daniel Helman, Meirav Barshimon, Mira Toister-Achituv
-
Publication number: 20140004593Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.Type: ApplicationFiled: March 14, 2013Publication date: January 2, 2014Inventors: Ferenc Boldog, Michael Heartlein
-
Publication number: 20140005356Abstract: The present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is in vivo incorporated instead of a tyrosine residue, and a method for producing the same. More specifically, the present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is incorporated instead of a tyrosine residue, and a method for producing the same, and a transformant for producing the recombinant mussel adhesive protein.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Inventors: Hyung Joon CHA, Byeongseon Yang, Yoo Seong Choi, Hyungdon Yun
-
Publication number: 20140004181Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: Morehouse School of MedicineInventors: Vincent Craig BOND, Michael Powell, Ming Bo Huang, Syed Ali
-
Publication number: 20140004608Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.Type: ApplicationFiled: May 22, 2013Publication date: January 2, 2014Applicant: CELLECTISInventors: Jean-Pierre Cabaniols, Andre Choulika, Christophe Delenda
-
Publication number: 20130344604Abstract: The present invention relates to an expression cassette useful for the expression of a polynucleotide sequence encoding a polypeptide.Type: ApplicationFiled: December 5, 2012Publication date: December 26, 2013Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Christel Aebischer-Gumy, Martin Bertschinger, Daniel Luescher, Pierre Moretti